Last reviewed · How we verify
Placebo plus Dexamethasone HFA
Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Asthma or chronic obstructive pulmonary disease (COPD) — Phase 3 trial indication likely respiratory inflammation.
At a glance
| Generic name | Placebo plus Dexamethasone HFA |
|---|---|
| Also known as | Decadron |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Immunology |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone is a synthetic glucocorticoid that exerts anti-inflammatory and immunosuppressive effects by activating intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced immune cell activation and infiltration. The HFA formulation is a metered-dose inhaler delivery system for pulmonary administration.
Approved indications
- Asthma or chronic obstructive pulmonary disease (COPD) — Phase 3 trial indication likely respiratory inflammation
Common side effects
- Tremor
- Headache
- Palpitations
- Nervousness
- Oral candidiasis
- Dysphonia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo plus Dexamethasone HFA CI brief — competitive landscape report
- Placebo plus Dexamethasone HFA updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI